Literature DB >> 15315626

Terlipressin increased the concentration of L-lactate in the rectal lumen in a patient with septic shock.

A Perner1, V L Jørgensen, T Waldau.   

Abstract

Terlipressin--a long-acting analogue of vasopressin--has been described to restore blood pressure in patients with catecholamine-resistant septic shock without obvious complications. We administered low-dose terlipressin (a single i.v.-bolus of 0.5 mg) to a patient with severe, hyperdynamic septic shock requiring high dosage of noradrenalin. After terlipressin the dose of noradrenalin could be reduced by 2/3 to obtain the same blood pressure. Two hours after terlipressin, the cardiac index had decreased from 6.2 to 3.3 l min(-1) m(-2) and the concentration of L-lactate in the rectal lumen, as assessed by equilibrium dialysis, increased from 3.6 to 7.2 mmol l(-1). In contrast, the systemic concentration of L-lactate was unaffected around 2.8 mmol l(-1). After 8 h the effect of terlipressin started to decline, and after an additional 12 h the systemic haemodynamics, dose of noradrenalin and concentrations of rectal and systemic L-lactate were the same as prior to the administration of terlipressin. As a strong vasopressor, terlipressin may have further impaired the metabolic dysfunction in the rectal mucosa either directly via vasoconstriction of mucosal vessels or through decreased cardiac output in this patient with noradrenalin-treated septic shock.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315626     DOI: 10.1111/j.0001-5172.2004.00442.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  2 in total

1.  Luminal lactate in acute pancreatitis--validation and relation to disease severity.

Authors:  Lauri Pynnönen; Minna Minkkinen; Sari Räty; Juhani Sand; Isto Nordback; Anders Perner; Jyrki Tenhunen
Journal:  BMC Gastroenterol       Date:  2012-04-30       Impact factor: 3.067

2.  Luminal concentrations of L- and D-lactate in the rectum may relate to severity of disease and outcome in septic patients.

Authors:  Vibeke L Jørgensen; Nanna Reiter; Anders Perner
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.